CL2022001477A1 - Using a kv7 potassium channel opener to treat pain - Google Patents

Using a kv7 potassium channel opener to treat pain

Info

Publication number
CL2022001477A1
CL2022001477A1 CL2022001477A CL2022001477A CL2022001477A1 CL 2022001477 A1 CL2022001477 A1 CL 2022001477A1 CL 2022001477 A CL2022001477 A CL 2022001477A CL 2022001477 A CL2022001477 A CL 2022001477A CL 2022001477 A1 CL2022001477 A1 CL 2022001477A1
Authority
CL
Chile
Prior art keywords
potassium channel
treat pain
channel opener
methods
subject
Prior art date
Application number
CL2022001477A
Other languages
Spanish (es)
Inventor
Philip Johnson James Jr
Beatch Gregory
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of CL2022001477A1 publication Critical patent/CL2022001477A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

En ciertas modalidades, la presente descripción se dirige a métodos para tratar el dolor en un sujeto, como un humano, en donde los métodos comprenden administrar oralmente una cantidad efectiva terapéuticamente de N-?4-(6-fluoro-3,4-dihidro-1H-isoquinolin-2-il)-2,6-dimetilfenil?-3,3-dimetilbutanamida (Compuesto A), al sujeto en necesidad de esta. La presente descripción se dirige además a varios métodos mejorados de terapia y administración del Compuesto A.In certain embodiments, the present disclosure is directed to methods of treating pain in a subject, such as a human, wherein the methods comprise orally administering a therapeutically effective amount of N-β4-(6-fluoro-3,4-dihydro -1H-isoquinolin-2-yl)-2,6-dimethylphenyl?-3,3-dimethylbutanamide (Compound A), to the subject in need thereof. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

CL2022001477A 2019-12-06 2022-06-03 Using a kv7 potassium channel opener to treat pain CL2022001477A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962945093P 2019-12-06 2019-12-06
US201962948010P 2019-12-13 2019-12-13

Publications (1)

Publication Number Publication Date
CL2022001477A1 true CL2022001477A1 (en) 2023-04-28

Family

ID=73856375

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001477A CL2022001477A1 (en) 2019-12-06 2022-06-03 Using a kv7 potassium channel opener to treat pain

Country Status (14)

Country Link
EP (1) EP4069211A1 (en)
JP (1) JP2023504166A (en)
KR (1) KR20220113411A (en)
CN (1) CN114786658A (en)
AU (1) AU2020397173A1 (en)
BR (1) BR112022010733A2 (en)
CA (1) CA3159436A1 (en)
CL (1) CL2022001477A1 (en)
CR (1) CR20220318A (en)
IL (1) IL293504A (en)
MX (1) MX2022006877A (en)
PE (1) PE20221169A1 (en)
TW (1) TW202133847A (en)
WO (1) WO2021113757A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113698345B (en) * 2021-10-27 2022-02-01 上海挚盟医药科技有限公司 Compounds as potassium channel modulators, their preparation and use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5419691B2 (en) 2006-08-23 2014-02-19 バレアント ファーマシューティカルズ インターナショナル Derivatives of 4- (N-azacycloalkyl) anilide as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
WO2013067591A1 (en) * 2011-11-10 2013-05-16 Relevare Australia Pty Ltd Topical formulations for pain management
US9248122B2 (en) * 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
RS64922B1 (en) * 2018-05-11 2023-12-29 Xenon Pharmaceuticals Inc Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener

Also Published As

Publication number Publication date
TW202133847A (en) 2021-09-16
KR20220113411A (en) 2022-08-12
CN114786658A (en) 2022-07-22
PE20221169A1 (en) 2022-07-25
CA3159436A1 (en) 2021-06-10
CR20220318A (en) 2022-10-07
JP2023504166A (en) 2023-02-01
AU2020397173A1 (en) 2022-06-23
WO2021113757A1 (en) 2021-06-10
EP4069211A1 (en) 2022-10-12
MX2022006877A (en) 2022-07-11
BR112022010733A2 (en) 2022-08-23
IL293504A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
MX2020009773A (en) Combination therapy.
CO2020015476A2 (en) Methods to enhance the bioavailability and exposure of a voltage-gated potassium channel opener
EA202092343A1 (en) TREATMENT OF PURULENT HYDRADENITIS WITH THE USE OF JAK INHIBITORS
MX2023007212A (en) Epinephrine spray formulations.
CL2021003034A1 (en) Methods of treatment of sjögren's syndrome using a bruton's tyrosine kinase inhibitor
CL2021003032A1 (en) Methods of treating chronic spontaneous urticaria using a Bruton's tyrosine kinase inhibitor.
MX2020001727A (en) Combination therapy.
CL2022001477A1 (en) Using a kv7 potassium channel opener to treat pain
CO2022008001A2 (en) Methods for treating depressive disorders
AR103118A1 (en) ANAMORELINE-BASED MEDICAL TREATMENTS
CL2023002321A1 (en) Voltage-activated potassium channel opener for use in the treatment of anhedonia.
CO2023014650A2 (en) Dosage and administration of recombinant l-asparaginase
EA201591603A1 (en) NEW THERAPEUTIC COMBINATIONS MYRTAZAPINE FOR APPLICATION IN PAIN DISEASES
GEP20227384B (en) Topical formulations comprising strontium and methylsulfonylmethane (msm) and methods of treatment
ZA202201446B (en) Methods of treating multifocal cancer
MX2022016410A (en) Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof.
CL2021001830A1 (en) lta4h inhibitors for the treatment of hidradenitis suppurativa
MX2022014005A (en) Pharmaceutical formulations of abiraterone acetate and niraparib.
MX2021001764A (en) Combination therapy.
EA202190294A1 (en) COMBINATION THERAPY FOR CANCER TREATMENT
AR114854A1 (en) METHODS FOR THE TREATMENT OF CANCER
CO2023011948A2 (en) Conjoint therapy for the treatment of seizure disorders
BR112022001796A2 (en) Focal treatment of prostate cancer
CL2022002064A1 (en) A pharmaceutical combination for the treatment of cancer
AR117120A1 (en) COMBINATION THERAPY INCLUDING A KRASG¹²C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS